Services
RNA sequencing (RNAseq) provides unbiased, specific, and sensitive quantification of coding and non-coding RNA transcripts. Alterations such as splice variants, gene fusions, mutations, and RNA editing events can easily be monitored.
RNAseq is the preferred method for numerous clinical applications including:
CellCarta leverages the power of next-generation sequencing (NGS) by using the NovaSeq X Plus, NovaSeq 6000, and NextSeq 550Dx platforms. We also offer other platforms such as NanoString nCounter, GeoMX Digital Spatial Profiler (DSP) and RNAScope that provide gene expression data with additional information on spatial biology.
Our offering spans from RNA extraction, library preparation, and sequencing, to data analysis and reporting.
To further support your findings, we provide orthogonal result validation using quantitative PCR and digital PCR.
Depletion of unwanted RNA molecules from the total RNA investigated is also offered.
We can implement and validate mRNA, microRNA, lncRNA assays or panels for any gene or gene set of interest.
We also offer numerous gene expression panels (mRNA, microRNA, and lncRNA) for a broad range of pathways and disease states.
Assays can also be developed with custom primers design.
Commercial Assays Available
TruSeq® Stranded mRNA Library Prep (Illumina®)
TruSeq® RNA exome library (Illumina®) RNA Prep with Enrichment, (L) Tagmentation kit (Illumina®)
Watchmaker RNA Library Prep Kit with Polaris® Depletion
Based on your sequencing needs, our team can develop a customized sequencing workflow which can be applied to various sample types, like-
Get insights on the mode of action underlying induced cellular phenotypes, reveal potential compound-induced toxicities or off-target effects, and compound similarities with our high throughput molecular cellular phenotyping service.
Our expert BioIT team can perform standard data analysis on bulk RNAseq data, such as gene/transcript quantification, fusion gene analysis, differential gene expression, gene set enrichment analysis (GSEA), but furthermore we have developed advanced workflows to perform variant calling and calculate expressed Tumor Mutational Burden (eTMB), detect MSI, perform immune deconvolution and HLA typing from the same bulk RNAseq data.
RNA profiling has emerged as a powerful tool to investigate the biomarker potential of human biofluids.
Our team published an RNA sequencing method using a dedicated RNA library kit to properly quantify extracellular RNA content and provide the complete transcriptome of a wide range of biofluids.
Our team implemented ASPYRE Lung as a CTA on liquid biopsy samples. This assay identifies actionable mutations on both cfDNA and cfRNA.
Learn more about performance assessment of total RNA sequencing of human biofluids and more.
Our expertise in RNA sequencing is showcased in numerous publications: